SPTX Latest Press Releases

-- October 9, 2026 --

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress Business Wire 1:00 PM

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo at the 39th European College of Neuropsychopharmacology (ECNP) Congress Business Wire 7:00 AM

-- October 7, 2026 --

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder and Sleep Disturbance Business Wire 1:00 PM

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance Business Wire 7:00 AM

-- September 14, 2026 --

Seaport Therapeutics to Participate in September Investor Conferences Business Wire 7:00 AM

-- September 9, 2026 --

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers Business Wire 1:14 PM

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers Business Wire 7:00 AM

-- August 31, 2026 --

Seaport Therapeutics to Present at Citi's 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference Business Wire 7:00 AM

-- August 3, 2026 --

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Business Wire 7:00 AM

-- June 9, 2026 --

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers Business Wire 2:00 AM

-- June 8, 2026 --

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Business Wire 7:05 AM

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo in Healthy Volunteers Business Wire 7:00 AM

-- June 1, 2026 --

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences Business Wire 7:00 AM

Market Data Delayed 15 Minutes